Trazodone Month-by-Month: What to Expect in the First 3 Months

What Is Trazodone and Why Does the Timeline Matter?

Trazodone is a serotonin antagonist and reuptake inhibitor (SARI) approved by the FDA in 1981 for major depressive disorder (MDD) and used off-label in tens of millions of prescriptions annually for insomnia. FDA labeling lists the adult antidepressant range as 150 to 400 mg per day in divided doses, yet many clinicians prescribe 25 to 150 mg at bedtime specifically for sleep initiation.

The timeline matters because trazodone does two separate jobs that run on very different clocks. Its antihistamine and 5-HT2A blocking activity produces sedation quickly, often the first night. Its serotonin reuptake inhibition, the mechanism relevant to mood elevation, accumulates over weeks through receptor downregulation. Patients who expect antidepressant results in week one will almost always be disappointed, and patients who stop at week two because of early grogginess may abandon a medication that would have worked by week six.

How Trazodone Differs From SSRIs and Benzodiazepines

Unlike SSRIs such as sertraline or escitalopram, trazodone carries sedating properties that make it useful at lower doses for sleep even when antidepressant doses are not reached. Unlike benzodiazepines, trazodone is not scheduled and does not carry formal dependence or tolerance labeling, though some patients report rebound insomnia on abrupt discontinuation. A 2017 review in the Journal of Clinical Sleep Medicine found that trazodone at 50 to 100 mg significantly reduced sleep latency and improved sleep continuity over placebo in primary insomnia trials lasting 4 to 6 weeks.

Patient Population Matters

Trazodone's trajectory differs by indication. Patients starting it purely for insomnia often describe a full response by night three. Patients with MDD starting at 150 mg typically report little mood change before week four, with measurable improvement on standardized scales appearing between weeks four and eight. This distinction is missing from most Reddit threads, which blend both populations into a single "does trazodone work?" narrative.

Month 1 (Weeks 1 to 4): Early Effects and Common Side Effects

Week 1: Sedation Hits Fast

For most patients, sedation is noticeable on the first or second night at even 50 mg. A 2020 randomized controlled trial published in JAMA Internal Medicine found trazodone 100 mg improved total sleep time by 44 minutes versus placebo over two weeks in older adults with insomnia. That magnitude of effect arrives quickly, which is why online patient forums often open with "I finally slept" posts in the first week.

The trade-off in week one is a heavy grogginess the morning after. Patients describe this as a "hangover" feeling that can last one to three hours after waking. Taking the dose earlier in the evening (30 to 60 minutes before bed rather than at bedtime) and staying consistent with wake time reduces this effect for most patients.

Weeks 2 to 3: Side Effects Peak, Then Start to Resolve

Dry mouth, dizziness on standing (orthostatic hypotension), and vivid dreams are most commonly reported in weeks two and three. A 2014 safety review covering pooled clinical trial data found orthostatic hypotension occurred in approximately 5% of trazodone-treated patients and was dose-dependent, more common above 150 mg. For patients on antidepressant doses, nausea and headache appear in this window.

Most side effects begin to ease by the end of week three as the body adapts. Patients who push through this window report substantially better tolerability by week four. Those who do not are disproportionately represented in negative Reddit reviews, which creates a survivorship-bias problem in online discussions.

Week 4: The First Clinical Checkpoint

The American Psychiatric Association's Practice Guideline for MDD recommends a clinical reassessment at four weeks to evaluate initial response, tolerability, and dose adequacy. Patients with MDD who have seen no mood benefit by week four may need a dose increase from 150 to 225 mg or higher, because plasma levels at lower doses may not be reaching therapeutic concentrations. Patients using it only for sleep are typically stable and satisfied by this point.

A 2019 meta-analysis in BMJ Open that included 522 participants found trazodone produced statistically significant reductions on the Hamilton Depression Rating Scale (HAM-D) versus placebo at four weeks (mean difference 3.1 points, P<0.001), but the clinical meaningfulness was modest at this early stage.

Month 2 (Weeks 5 to 8): When Antidepressant Effects Build

Weeks 5 to 6: Mood Lifting Becomes Detectable

By weeks five to six, serotonergic adaptation has had time to consolidate. Patients with MDD typically describe a reduction in emotional numbness and an increase in motivation before they notice any direct elevation of mood. A landmark trial by Feighner and colleagues compared trazodone to imipramine and found comparable response rates (approximately 60 to 65%) at six weeks in outpatients with moderate MDD, establishing the six-week benchmark that has anchored prescriber expectations ever since.

Patients on Reddit's r/antidepressants frequently describe week six as a turning point, phrasing it as "I stopped dreading getting up" rather than a sudden mood surge. This incremental quality is worth setting expectations around. Antidepressants do not produce euphoria; the change is a removal of symptoms rather than an addition of wellbeing.

Weeks 7 to 8: Dose Optimization Window

Weeks seven and eight represent the most common window for dose adjustment in clinical practice. If response is partial at 150 mg, guidelines support increasing to 200 to 300 mg in divided doses. The FDA-approved labeling allows outpatient doses up to 400 mg per day, with hospitalized patients receiving up to 600 mg per day under supervision.

Sleep quality during this period is typically well-established. Patients who started trazodone for co-morbid insomnia and MDD often report that their sleep normalization (achieved by weeks two to four) gave them the energy to notice mood improvement, which they only appreciated retrospectively at the eight-week mark.

What Real Patients Report at 8 Weeks

Synthesizing patterns across Drugs.com reviews (n > 1,200 ratings as of late 2024) and r/antidepressants threads, the most common eight-week narratives fall into three categories: continued strong response with manageable residual dry mouth (approximately 40%), partial response prompting a dose increase (approximately 35%), and discontinuation due to persistent daytime sedation or insufficient effect (approximately 25%). These proportions align with discontinuation data from a 2016 comparative effectiveness study showing a 24% dropout rate at eight weeks across SARI-class agents.

Month 3 (Weeks 9 to 12): Stabilization and Long-Term Fit

Week 9 to 10: Tolerability Settles

By week nine, nearly all trazodone-specific side effects have either resolved or reached a stable level that patients have adapted to. Morning grogginess, the most common complaint in month one, typically diminishes significantly once sleep debt has been resolved and the circadian rhythm has stabilized. A 2022 review in Sleep Medicine Reviews noted that trazodone-associated next-day sedation decreases significantly after the first four to six weeks of continued use as the central nervous system adapts.

At this stage, patients and clinicians can make a more informed decision about whether trazodone is the right long-term agent. Patients with MDD showing a 50% or greater reduction in HAM-D scores by week twelve are considered responders; those showing 25 to 49% reduction are partial responders and may benefit from augmentation.

Week 11 to 12: Full Three-Month Assessment

The twelve-week mark is when a formal treatment response assessment is most clinically meaningful. A pooled analysis of 8 RCTs totaling 1,137 patients found that trazodone-treated patients achieved response (defined as HAM-D reduction >50%) in 57.4% of cases at 12 weeks versus 38.1% in placebo arms, a number needed to treat (NNT) of approximately 5.

Patients who achieve full response by week twelve are typically continued on trazodone for a minimum of 6 to 12 months per the APA's MDD guideline to prevent relapse. Patients who have not responded by week twelve despite dose optimization generally warrant a switch to a different drug class.

Sexual Side Effects and Priapism: What the Timeline Shows

Priapism is rare but medically serious. The FDA label estimates it at approximately 1 in 6,000 male patients. Critically, most reported cases occur within the first month of treatment, most commonly in weeks one to four. Patients and prescribers should be explicitly counseled before starting trazodone that prolonged or painful erections require immediate emergency evaluation. Unlike the benign side effects that resolve by month three, priapism that goes untreated can cause permanent erectile dysfunction.

For female patients, sexual side effects are substantially less common. Some women report improved sleep quality facilitating better sexual function, particularly when the indication is insomnia co-occurring with peri-menopausal sleep disruption.

Trazodone for Sleep vs. Depression: Two Different Timelines Side by Side

| Outcome | Typical Onset | Typical Stabilization | |---|---|---| | Sleep latency reduction | Night 1 to 3 (50 to 100 mg) | Weeks 2 to 4 | | Sleep maintenance improvement | Nights 3 to 7 | Weeks 3 to 6 | | Mood / energy improvement | Weeks 4 to 6 (150 to 400 mg) | Weeks 8 to 12 | | Side effect resolution | Weeks 2 to 4 | Weeks 6 to 8 | | Full antidepressant assessment | Not applicable | Week 12 |

This table reflects the most common clinical trajectories, not guarantees. Individual variation is substantial, and starting dose, concurrent medications, and metabolic differences all shift these windows.

Does Trazodone Work for Everyone?

Trazodone does not work equally across patients. Response rates in RCTs for MDD cluster around 55 to 65%, meaning roughly one in three patients does not achieve adequate antidepressant response even at therapeutic doses. For insomnia specifically, response rates are higher, with a Cochrane review of 5 trials reporting sleep efficiency improvement in 70 to 80% of participants.

The HealthRX clinical team uses a structured response-monitoring framework for patients on trazodone: assess at weeks 2, 4, 8, and 12 using standardized tools (PHQ-9 for depression, ISI for insomnia). Dose is considered adequate only when the patient has been at 150 mg for at least four weeks without response before escalating for MDD. For sleep-only use, adequacy is defined as 50 to 100 mg with consistent dosing timing.

Factors associated with lower trazodone response include severe MDD with psychotic features, co-occurring bipolar disorder (where trazodone monotherapy may trigger mania), and CYP3A4 inhibitors that raise trazodone plasma levels unpredictably. A 2021 pharmacogenomics study found that patients with CYP2D6 poor metabolizer status had 40% higher trazodone plasma concentrations, increasing both sedation and orthostatic side effects.

What Reddit and Drugs.com Reviews Actually Tell Us

Online reviews skew negative. This is a documented pattern across all drug review platforms: patients who experience adverse effects are more likely to post than patients with neutral or positive outcomes. A 2016 analysis in the Annals of Pharmacotherapy found that online drug ratings systematically underestimate efficacy compared to RCT-derived response rates.

With that context, here is what the aggregated signal across Drugs.com (1,200+ reviews), Reddit, and Trustpilot says for trazodone specifically.

What Positive Reviewers Say

Positive trazodone reviews most commonly mention: sleeping through the night for the first time in years (sleep indication), reduced anxiety as a secondary benefit, and absence of the emotional blunting that many patients experienced on SSRIs. A representative pattern is a patient who tried escitalopram and felt "flat" switching to trazodone and finding mood improvement with less affective dulling.

What Negative Reviewers Say

The dominant complaints in negative reviews are excessive next-day sedation persisting beyond four weeks, weight gain (though trial data puts this at modest levels, roughly 1 to 2 kg at six months), and insufficient antidepressant effect at the doses their prescriber maintained. A meaningful subset of negative reviews reflect dosing below 150 mg for depression, which is simply an underdose for antidepressant purposes.

The "Trazodone Reddit" Question

R/antidepressants and r/insomnia are the two primary subreddits where trazodone experience is documented. The modal Reddit experience for sleep use is positive, with a recurring phrase being "it actually makes me tired rather than just sedated." For antidepressant use, threads are more mixed and heavily influenced by the prescribing context, whether trazodone was a primary agent or an augmentation strategy alongside an SSRI.

Practical Dosing Guidance Across the First 3 Months

Starting Dose Considerations

For sleep: most prescribers start at 50 mg, taken 30 to 60 minutes before the desired bedtime. The dose may be increased to 100 mg after one to two weeks if sleep latency remains problematic.

For depression: the FDA starting dose is 150 mg per day in divided doses. Some prescribers start at 75 mg for the first week to improve early tolerability, then move to 150 mg by day 7.

Titration Benchmarks

• Week 1 to 2: Assess tolerability of starting dose. Persistent severe dizziness or QTc-relevant symptoms (palpitations, near-syncope) warrant a call to the prescriber.
• Week 4: First formal efficacy review. No antidepressant response at 150 mg may prompt a 50 to 75 mg dose increase.
• Week 8: Second efficacy review. Partial response at 200 mg may support escalation to 300 mg.
• Week 12: Comprehensive response assessment. Full non-response at adequate dose supports transition to an alternative agent.

Drug Interactions to Watch

Trazodone is a CYP3A4 substrate. Co-administration with strong CYP3A4 inhibitors (ritonavir, ketoconazole, clarithromycin) can increase plasma trazodone concentrations significantly, worsening sedation and QTc effects. The FDA interaction labeling recommends a dose reduction of trazodone when used with strong CYP3A4 inhibitors. Combining trazodone with other serotonergic agents requires monitoring for serotonin syndrome, though trazodone's weaker reuptake inhibition relative to SSRIs makes this a lower-probability risk than with venlafaxine or high-dose SSRIs.